<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15103">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02097108</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_HIV1</org_study_id>
    <nct_id>NCT02097108</nct_id>
  </id_info>
  <brief_title>Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir</brief_title>
  <official_title>One Arm, Open Label, Interventional, Non-comparative Study to Assess Changes in Lipids and Lipoproteins in HIV Infected Women With Hyperlipidemia After Switch From Boosted Protease Inhibitor to Raltegravir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 24-week, one arm, open-label, interventional, non-comparative multicenter study to
      evaluate lipid changes in HIV infected women with hyperlipidemia on boosted PI based regimen
      after switching their boosted PI to raltegravir at standard dosage with 400mg twice daily.

      This study aims to study the effect on metabolic profiles by switching hyperlipidemic HIV
      infected women from a PI based regimen to raltegravir.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction in the plasma concentration of cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>A reduction of &gt; 5% in the plasma concentration of direct LDL cholesterol from baseline to week 12 or &gt; 10% reduction of total cholesterol or reduction of lipid lowering agents is expected. Reduction of lipid lowering agents is defined as reduction due to amelioration of lipid profiles and does not include reduction due to side effects or other toxicity issues.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes from baseline in total cholesterol, triglycerides and HDL cholesterol over time</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluate risk reduction of cardiovascular risk during the treatment period according to Framingham risk score</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be offered to switch their protease inhibitor containing regimen to a raltegravir (400mg twice daily, orally) based regimen while maintaining the same background therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <arm_group_label>Raltegravir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV-1 infection in female patients, age ≥18 years

          -  Patients receiving antiretroviral therapy consisting of at least 2 antiretroviral
             agents other than protease inhibitor plus a ritonavir-boosted protease inhibitor (PI)
             for at least the previous 6 months

          -  Plasma HIV viral load &lt;50 copies/ml on current boosted PI containing regimen for ≥ 6
             months prior to study entry

          -  Fasting LDL cholesterol &gt;130 mg/dl

          -  Fasting triglycerides &lt;450 mg/dl

        Exclusion Criteria:

          -  History of virological failure during previous antiretroviral therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Greil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMU Salzburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PMU Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ninon Taylor, MD</last_name>
      <email>n.taylor@salk.at</email>
    </contact>
    <investigator>
      <last_name>Richard Greil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AKH Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Armin Rieger, MD</last_name>
      <email>armin.rieger@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Armin Rieger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottto Wagner Spital</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigitte Schmied, MD</last_name>
      <email>brigitte.schmied@wienkav.at</email>
    </contact>
    <investigator>
      <last_name>Brigitte Schmied, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV infection</keyword>
  <keyword>Raltegravir</keyword>
  <keyword>Switch</keyword>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Women</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
